Clinical trial · Interventional
Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617
NCT05170555CI-TRIAL-00055688unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Renal Cell Carcinoma (RCC) is the second most common tumor in urology. Considering its origination from kidney, an organ with intense physiological uptake and excretion of 68Ga-PSMA, this study aims to evaluate the uptake of 68Ga-PSMA in RCC compared to 18F-FDG in the same patients, and assess the feasibility of 177Lu-EB-PSMA-617 treatment in patients with the advanced RCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 | Drug | — | UNRESOLVED |
| 68Ga-PSMA | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-PSMA, PET/CT and 177Lu-EB- PSMA-617 therapy
- description
- All patients diagnosed with RCC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
- interventionNames
- Drug: 68Ga-PSMA
- Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Primary outcomes (1)
- measure
- Diagnostic value
- timeFrame
- through study completion, an average of 1 year
- description
- Sensitivity and Specificity of 68Ga-PSMA PET/CT for Renal Cell Carcinoma in comparison with 18F-FDG PET/CT
Secondary outcomes (1)
- measure
- Safety of therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * confirmed treated or untreated renal cell carcinoma patients; * 68Ga-PSMA PET/CT and 18F-FDG PET/CT within two weeks; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * known allergy against PSMA * any medical condition that in the opinion of the investigator may significantly interfere with study compliance
References
Publications (0)
Data not yet available
No reference posted for this study.